Nathalie Cools

Nathalie Cools

Nathalie Cools

CEO - Anicells

Prof. dr. Nathalie Cools currently is appointed with a 50% associate professorship at the Faculty of Medicine and Health Sciences of the University of Antwerp and is senior lead scientist of the Immune Regulation and tolerance-inducing Strategies (IRiS) research group at the Faculty of Medicine and Health Sciences of the University of Antwerp. The main research interests of the IRiS team focus on immunobiology of human dendritic cells in the pathogenesis of autoimmunity and their modulation in order to provide the prospect for their use to suppress pathogenic immune responses in autoimmune diseases such as multiple sclerosis (MS). MS is the most common disabling neurologic disease of young people, affecting approximately one in thousand people in Europe. Our research has demonstrated that dendritic cells of MS patients are in an “hyper-activated” state setting a cascade of processes in motion that ultimately results in damage to the body's own myelin. In contrast, when dendritic cells were generated in the laboratory under the influence of vitamin D, so-called tolerance-inducing or tolerogenic DC (tolDC) were created being able to re-educate the immune system not to react against myelin. Currently, this novel tolDC approach is being moved forward to a first phase I study in patients with MS. To date, a dose-escalation clinical trial for a clinical-grade vitamin D3-treated tolDC product has been approved by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium. Nathalie Cools has a strong background in immunology, including cellular biology and flow cytometry, with a particular emphasis on immune monitoring of experimental human vaccination studies. Her research has resulted in more than 50 scientific publications (of which 28 as first or last author) in peer-reviewed international journals .

Join us in person on 19 May

Flanders.bio Strategic Partners

Flanders.bio Supporting Partners